- 3 insiders purchased BioAmber stock within one month.
- The stock was sold by no insiders in the month of intensive purchasing.
- All 3 of these insiders increased their holdings by more than 10% each.
BioAmber (NYSE:BIOA) produces and sells bio-succinic acid to customers in various chemical markets in the United States.
Insider buying during the last 30 days
Here is a table of BioAmber's insider activity during the last 30 days.
|Name||Title||Trade Date||Shares Purchased||Current Ownership||Increase In Shares|
|Jean-Francois Huc||CEO||May 12||3,000||20,345 shares||+17.3%|
|Michael Hartmann||EVP||May 12||2,500||21,220 shares||+13.4%|
|Andrew Ashworth||CFO||May 12||3,000||3,000 shares||from 0 to 3,000|
There have been 8,500 shares purchased by insiders during the last 30 days.
Insider buying by calendar month
Here is a table of BioAmber's insider activity by calendar month.
|Month||Insider buying / shares||Insider selling / shares|
There have been 35,700 shares purchased and there have been zero shares sold by insiders since May 2013. BioAmber had its IPO in May 2013.
BioAmber reported the first-quarter financial results on May 8 with the following highlights:
|Net loss||$19.9 million|
|Adjusted net loss||$8.3 million|
The three insiders purchased their shares after these results.
BioAmber expects to have its Sarnia plant completed in early 2015.
|Qtrly Rev Growth (yoy):||0.06||0.00||-0.01|
|PEG (5 yr expected):||N/A||2.38||9.00|
BioAmber is still building its Sarnia plant.
There have been three different insiders buying BioAmber, and there have not been any insiders selling BioAmber during the last 30 days. All three of these insiders increased their holdings by more than 10% each.
The three insiders purchased their shares at prices ranging from $10.00 to $10.17. I believe BioAmber could be a good pick below $10.17 based on the intensive insider buying.
Editor's Note: This article discusses one or more securities that do not trade on a major exchange. Please be aware of the risks associated with these stocks.